VTGN News and Press, VistaGen Therapeutics Inc. From 02/08/23

VistaGen Therapeutics (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is reporting on its fiscal year 2023 third quarter e...

VistaGen Therapeutics press release ( NASDAQ: VTGN ): Q3 GAAP EPS of -$0.05 beats by $0.02 . Revenue of $0.18M (-50.0% Y/Y) misses by $0.13M . At December 31, 2022, the Company had cash and cash equivalents of approximately $25.0 million. For further details see:...

Pherin acquisition completed; all future royalty payment obligations related to PH94B and PH10 eliminated, three new drug candidates added to Vistagen’s pipeline PH94B Phase 3 program for social anxiety disorder advancing towards important next steps PH10 Phase 1 study init...

Vistagen (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has announced that it will host a conference call and webcast at ...

Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced it will host a conference call and webcast on Tuesday, February ...

Vistagen (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, today announced the closing of its acquisition of Pherin Pharmace...

Acquisition eliminates all future royalty payment obligations for PH94B and PH10 and expands Vistagen's pipeline Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and othe...

3 Things That Impact the Price of Penny Stocks Penny stocks are stocks that trade for low prices, typically less than $5 per share. The price of penny stocks is influenced by several factors. Speculation is one of the main factors that impacts penny stock prices. Investors often buy penny s...

VistaGen Therapeutics (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, announced that the first cohort of healthy volunteer...

Small U.S. Phase 1 trial with newly optimized formulation to confirm favorable safety profile from three previous clinical trials and facilitate Phase 2B development of PH10 as a stand-alone treatment for major depressive disorder Vistagen (NASDAQ: VTGN) a late clinical-stage biopha...